Does Lamivudine And Tenofovir Disoproxil Fumarate Interact with Velpatasvir And Sofosbuvir?
CDI records a moderate classification for Lamivudine And Tenofovir Disoproxil Fumarate and Velpatasvir And Sofosbuvir. The stored summary is: Increases tenofovir exposure. Monitor for adverse reactions associated with tenofovir. The mechanism involves increases tenofovir exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Lamivudine And Tenofovir Disoproxil Fumarate Class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Velpatasvir And Sofosbuvir Class
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Increases tenofovir exposure
What To Tell Your Doctor or Pharmacist
If you are taking Lamivudine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Velpatasvir And Sofosbuvir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider